## **RET** @ CRICK

## RET Research Collaborative Network Inaugural Meeting Monday 10<sup>th</sup> June, 2019

## The Francis Crick Institute, 1 Midland Road, London, NW1 1AT

CPD accreditation with Royal College of Physicians applied for

## Programme

8-9	Registration (tea/coffee/croissants)
9 – 9.10	Welcome: Tom Kurzawinski and Rakhee Chauhan
Session 1.	An Introduction to RET and MEN2
	Chairs: Prof Raj Thakker, Mrs. Jo Grey
9.10 - 9.35	A RETrospective view of GDNF signalling
	Prof. Neil McDonald, Senior Group Leader, the Francis Crick Institute
9.35 - 10.00	Testing for RET (indications, results, VUS).
	Dr. Louise Izatt, Consultant in Clinical Genetics at Guy's and St Thomas' NHS
	Foundation Trust and King's College London
10.00 - 10.25	Thyroid surgery in MEN2; A Gospel according to RET?
	Mr. Tom Kurzawinski, Consultant Endocrine Surgeon UCLH & GOSH
10.25 - 10.50	A closer look into how RET point mutations influence MEN2 phenotypes
	Dr Rakhee Chauhan, Postdoctoral Research Fellow, The Francis Crick Institute
10.50 - 10.55	Session Discussion
10.55 - 11.15	Networking tea/coffee break.
Session 2.	RET and Hirschsprung's disease.
	Chairs: Dr Nikhil Thapar, TBC
11.15 - 11.40	Mouse modelling of RET induced Hirschsprung's disease.
	Prof. Robin Lovel-Badge / Rosalyn Flowers, Senior Group Leader / PhD student The
	Francis Crick Institute
11.40 - 12.05	Identification, treatment and genetics of Hirschsprung's disease.
	Dr Robert MW Hofstra, Head of Department of Clinical Genetics, Erasmus MC,
	Rotterdam, Netherland
12.05 - 12.30	Structural insights into RET folding
	Dr. Svend Kjaer, STP Deputy The Francis Crick Institute
12.30 - 12.40	Session Discussion
12.40 - 13.30	Networking Lunch

Session 3.	Diverse Roles of RET.
	Chairs: Prof Marta Korbonits, Dr Caroline Brain
13.30 - 13.55	The Pituitary and RET.
	Clara Alvarez, Professor of Physiology, Santiago de Compostela, Spain
13.55 - 14.20	Parkin regulates Ret protein levels
	Dr. Edgar Kramer, Group Leader University of Plymouth
14.20 - 14.45	Novel functions in RET signalling; RET and GFRAL in
	body weight regulation.
	Dr. Sebastian Jørgensen, Novo Nordisk
14.45 - 15.10	Activation of RET signalling improves haematopoietic
	stem cell potency and bone marrow transplantation.
	Dr. William Grey, Postdoctoral Research Fellow, the Francis Crick Institute
15.10 - 15.35	Session Discussion.
15.35 - 15.55	Networking tea/coffee break.
Session 4.	Targeting RET in Oncology.
	Chairs: Dr Rakhee Chauhan, Prof Ashley Grossman
15.55 - 16.20	RET fusions in NSCLC; insights from the TracerX project.
	Dr Crispin Hiley, Senior Lecturer & Consultant Clinical Oncologist UCLH
16.20 - 16.45	Therapy of human cancers with RET fusion; from multiple kinase inhibitors to
	specific inhibitors
	Dr. Takashi Kohno, Chief of the Division of Genome Biology, National Cancer
	Centre Research Institute, Japan
16.45 - 17.10	Targeting RET clinically: past and present therapeutics
	Dr. Kate Newbold, Consultant Clinical Oncologist, The Royal Marsden, London, UK
17.10 - 17.35	Next generation RET inhibitors; the future is here! Blueprint BLU-667 clinical
	efficacy in lung cancer and MTC.
	Dr Martin Foster, Associate Professor and Consultant in Medical Oncology,
	UCL Cancer Institute / UCLH
17.35 – 17.45	Session Discussion
17.45 - 17.50.	Closing Remarks
	Drinks Reception/Networking Evening at Crick

To book your free place, scan the QR code or visit <u>www.eventbrite.com/e/retcrick-</u>

tickets-52393900567

